We’d love to hear your feedback on this activity. It helps us to continually improve our products.
The benefit of chemotherapy addition to endocrine therapy remains controversial in premenopausal patients. In this touchONCOLOGY interview Dr Oleg Gluz (West German Study Group, Mönchengladbach, Germany) discusses the ongoing phase III ADAPT cycle trial investigating the impact of age, recurrence score, and ovarian function suppression on endocrine therapy response. The abstract entitled ‘Impact of age, […]
It was a pleasure to speak with Prof Winette van der Graaf (The Netherlands Cancer Institute, Amsterdam, Netherlands) to hear about her aims for the European Organisation for Research and Treatment of Cancer (EORTC) during her presidency, and the current initiatives the society are focusing on. Disclosures: Winette van der Graaf has no financial or […]
Prof Winette van der Graaf (The Netherlands Cancer Institute, Amsterdam, Netherlands) shares some exciting highlights to look forward to at the 60th anniversary event being held in September 2022 and why healthcare professionals should attend. Questions What are the key highlights of the upcoming EORTC 60th anniversary event in September? (00:25-03:23) Why should healthcare professionals […]
Prof Winette van der Graaf (The Netherlands Cancer Institute, Amsterdam, Netherlands) celebrates strengths of the European Organisation for Research and Treatment of Cancer (EORTC) and what makes the society unique. She also adds that an ongoing major challenge is obtaining funding for clinical trials and how they are trying to overcome this. Disclosures: Winette van […]
Cabozantinib is a targeted therapy used to treat many forms of cancers. Prof. Robert Jones (University of Glasgow, Scotland, United Kingdom) discusses the rationale, design, and findings of the randomised phase 2 ATLANTIS trial, of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma. Questions: What is the rationale for the use of cabozantinib in the […]
Dr William Townsend shares the latest data from the final analysis of the phase III GALLIUM study, which used the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab plus chemotherapy to follicular lymphoma. The study compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma. The abstract ‘OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM […]
In Part Two of this interview, Dr Mazyar Shadman (Fred Hutchinson Cancer Center, Seattle, Was, USA) presents the results of the follicular lymphoma cohort from his ongoing phase I/II clinical trial investigating MB-106 for B-cell lymphoma/CLL. He discusses the positive efficacy and safety data and the next steps in the clinical development of MB-106. Abstract […]
In part one of this interview, Dr Mazyar Shadman (Fred Hutchinson Cancer Center, Seattle, Was, USA) discusses the challenges of CAR-T therapy for follicular lymphoma and the advantages of MB-106, a third-generation, CD20-targeted, autologous CAR-T cell therapy over earlier generation CAR-T therapies. Abstract S207: ‘EFFICACY AND SAFETY OF A THIRD GENERATION CD20 CART (MB-106) FOR […]
In Part One of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. A total of 55 patients were treated and the combination therapy showed complete molecular response. These […]
Get the latest clinical insights from touchONCOLOGY